Screener
ANI Pharmaceuticals ANIP Goodwill
Goodwill at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Property and equipment, net | 73,223 | 62,476 |
| Deferred tax assets, net | 71,495 | 69,072 |
| Intangible assets, net | 449,857 | 479,526 |
| Goodwill | 62,480 | 62,480 |
| Other non-current assets | 11,624 | 13,706 |
| Total Assets | $1,494,112 | $1,440,377 |
| Liabilities and Stockholders’ Equity | ||
| Current Liabilities |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's goodwill?
- ANI Pharmaceuticals (ANIP) reported goodwill of $62.48M in Q2 2026.
- How has ANI Pharmaceuticals's goodwill changed year-over-year?
- ANI Pharmaceuticals's goodwill increased by 3.2% year-over-year, from $60.53M to $62.48M.
- What is the long-term trend for ANI Pharmaceuticals's goodwill?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's goodwill has grown at a 77.2% compound annual growth rate (CAGR), from $3.58M to $62.48M.
- What does goodwill mean?
- The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.
Ask your AI about ANI Pharmaceuticals's goodwill.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude